CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 20 enrolled
Drug / intervention
Adalimumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01243671
NCT01243671Phase 3Completed
CompareCT.gov

A Multi-Center Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease

AbbVie (prior sponsor, Abbott)·interventional·Posted Nov 18, 2010·Updated Jul 25, 2014

In Brief

A Phase 3 clinical trial evaluating Adalimumab for Intestinal Behçet's Disease. Completed, enrolled 20 participants across 12 sites.

Detailed Summary

To investigate efficacy, safety and pharmacokinetics of adalimumab subcutaneous (sc) for Japanese subjects with intestinal Behçet's disease who are refractory to conventional therapies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntestinal Behçet's Disease
CountriesJapan
CollaboratorsEisai Co., Ltd.

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 18, 2010
Enrollment StartOct 1, 2010
Primary CompletionMar 1, 2012
Study CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 15.6 years ago

Interventions

Adalimumabbiological